{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:05:20Z","timestamp":1787025920491,"version":"build-2736575974"},"reference-count":63,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2024.0094","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T07:34:36Z","timestamp":1722411276000},"source":"Crossref","is-referenced-by-count":5,"title":["Multiple endocrine neoplasia type 1"],"prefix":"10.3238","author":[{"given":"Jerena","family":"Manoharan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max B.","family":"Albers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Rinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Adelmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannis","family":"G\u00f6rlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef K.","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2024,8,9]]},"reference":[{"key":"10.3238\/arztebl.m2024.0094_ref1","doi-asserted-by":"crossref","unstructured":"Brandi ML, Agarwal SK, Perrier ND, Lines KE, Valk GD, Thakker RV: Multiple endocrine neoplasia type 1: latest insights. Endocr Rev 2021; 42: 133–70.","DOI":"10.1210\/endrev\/bnaa031"},{"key":"10.3238\/arztebl.m2024.0094_ref2","doi-asserted-by":"crossref","unstructured":"Goudet P, Cadiot G, Barlier A, et al.: French guidelines from the GTE, AFCE and ENDOCAN-RENATEN (Groupe d’\u00e9tude des Tumeurs Endocrines\/Association Francophone de Chirurgie Endocrinienne\/Reseau national de prise en charge des tumeurs endocrines) for the screening, diagnosis and management of Multiple endocrine neoplasia type 1. Ann Endocrinol (Paris) 2024; 85: 2–19.","DOI":"10.1016\/j.ando.2023.09.003"},{"key":"10.3238\/arztebl.m2024.0094_ref3","doi-asserted-by":"crossref","unstructured":"Chandrasekharappa SC, Guru SC, Manickam P, et al.: Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997; 276: 404–7.","DOI":"10.1126\/science.276.5311.404"},{"key":"10.3238\/arztebl.m2024.0094_ref4","doi-asserted-by":"crossref","unstructured":"Manoharan J, Albers MB, Bartsch DK: The future: diagnostic and imaging advances in MEN1 therapeutic approaches and management strategies. Endocr Relat Cancer 2017; 24: T209–25.","DOI":"10.1530\/ERC-17-0231"},{"key":"10.3238\/arztebl.m2024.0094_ref5","doi-asserted-by":"crossref","unstructured":"Goudet P, Murat A, Binquet C, et al.: Risk factors and causes of death in MEN1 disease. A GTE (Groupe d’Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg 2010; 34: 249–55.","DOI":"10.1007\/s00268-009-0290-1"},{"key":"10.3238\/arztebl.m2024.0094_ref6","doi-asserted-by":"crossref","unstructured":"Ito T, Igarashi H, Uehara H, Berna MJ, Jensen RT: Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1\/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Medicine (Baltimore) 2013; 92: 135–81.","DOI":"10.1097\/MD.0b013e3182954af1"},{"key":"10.3238\/arztebl.m2024.0094_ref7","doi-asserted-by":"crossref","unstructured":"Norton JA, Krampitz G, Zemek A, Longacre T, Jensen RT: Better survival but changing causes of death in patients with multiple endocrine neoplasia type 1. Ann Surg 2015; 261: e147–8.","DOI":"10.1097\/SLA.0000000000001211"},{"key":"10.3238\/arztebl.m2024.0094_ref8","doi-asserted-by":"crossref","unstructured":"Casey RT, Saunders D, Challis BG, et al.: Radiological surveillance in multiple endocrine neoplasia type 1: a double-edged sword? Endocr Connect 2017; 6: 151–8.","DOI":"10.1530\/EC-17-0006"},{"key":"10.3238\/arztebl.m2024.0094_ref9","doi-asserted-by":"crossref","unstructured":"Gaujoux S, Martin GL, Miralli\u00e9 E, et al.: Life expectancy and likelihood of surgery in multiple endocrine neoplasia type 1: AFCE and GTE cohort study. Br J Surg 2022; 109: 872–879.","DOI":"10.1093\/bjs\/znac006"},{"key":"10.3238\/arztebl.m2024.0094_ref10","doi-asserted-by":"crossref","unstructured":"Falchetti A: Genetics of multiple endocrine neoplasia type 1 syndrome: what’s new and what’s old. F1000Research 2017; 6.","DOI":"10.12688\/f1000research.7230.1"},{"key":"10.3238\/arztebl.m2024.0094_ref11","doi-asserted-by":"crossref","unstructured":"Alrezk R, Hannah-Shmouni F, Stratakis CA: MEN4 and CDKN1B mutations: The latest of the MEN syndromes. Endocr Relat Cancer 2017; 24: T195–208.","DOI":"10.1530\/ERC-17-0243"},{"key":"10.3238\/arztebl.m2024.0094_ref12","doi-asserted-by":"crossref","unstructured":"Thakker RV, Newey PJ, Walls GV, et al.: Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012; 97: 2990–3011.","DOI":"10.1210\/jc.2012-1230"},{"key":"10.3238\/arztebl.m2024.0094_ref13","doi-asserted-by":"crossref","unstructured":"Manoharan J, Raue F, Lopez CL, et al.: Is routine screening of young asymptomatic MEN1 patients necessary? World J Surg 2017; 41: 2026–32.","DOI":"10.1007\/s00268-017-3992-9"},{"key":"10.3238\/arztebl.m2024.0094_ref14","doi-asserted-by":"crossref","unstructured":"Goudet P, Dalac A, Le Bras M, et al.: MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d’\u00e9tude des Tumeurs Endocrines. J Clin Endocrinol Metab 2015; 100: 1568–77.","DOI":"10.1210\/jc.2014-3659"},{"key":"10.3238\/arztebl.m2024.0094_ref15","doi-asserted-by":"crossref","unstructured":"Pieterman CRC, Valk GD: Update on the clinical management of multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf) 2022; 97: 409–23.","DOI":"10.1111\/cen.14727"},{"key":"10.3238\/arztebl.m2024.0094_ref16","unstructured":"Gress TM, Albert J, Alfke H, et al.: [Practice guideline neuroendocrine tumors—AWMF-Reg. 021–27]. Z Gastroenterol 2018; 56: 583–681."},{"key":"10.3238\/arztebl.m2024.0094_ref17","doi-asserted-by":"crossref","unstructured":"Hofland J, Falconi M, Christ E, et al.: European Neuroendocrine Tumor Society (ENETS) 2023 Guidance Paper for functioning pancreatic neuroendocrine tumour syndromes. J Neuroendocrinol 2023; 35: e13318.","DOI":"10.1111\/jne.13318"},{"key":"10.3238\/arztebl.m2024.0094_ref18","doi-asserted-by":"crossref","unstructured":"Niederle B, Selberherr A, Bartsch DK, et al.: Multiple endocrine neoplasia type 1 and the pancreas: diagnosis and treatment of functioning and non-functioning pancreatic and duodenal neuroendocrine neoplasia within the MEN1 syndrome—an international consensus statement. Neuroendocrinology 2021; 111: 609–30.","DOI":"10.1159\/000511791"},{"key":"10.3238\/arztebl.m2024.0094_ref19","doi-asserted-by":"crossref","unstructured":"de Laat JM, Dekkers OM, Pieterman CRC, et al.: Long-term natural course of pituitary tumors in patients with MEN1: results from the DutchMEN1 study group (DMSG). J Clin Endocrinol Metab 2015; 100: 3288–96.","DOI":"10.1210\/JC.2015-2015"},{"key":"10.3238\/arztebl.m2024.0094_ref20","doi-asserted-by":"crossref","unstructured":"Peipert BJ, Goswami S, Yount SE, Sturgeon C: Health-related quality of life in MEN1 patients compared with other chronic conditions and the United States general population. Surgery 2018; 163: 205–11.","DOI":"10.1016\/j.surg.2017.04.030"},{"key":"10.3238\/arztebl.m2024.0094_ref21","doi-asserted-by":"crossref","unstructured":"Manoharan J, Bartsch DK: Heredit\u00e4rer prim\u00e4rer Hyperparathyreoidismus BT – Viszeral- und Allgemeinchirurgie. In: Kreis M, Bartsch DK, Lang H (eds.): Berlin, Heidelberg: Springer Berlin Heidelberg 2021; 1–16.","DOI":"10.1007\/978-3-662-61724-3_25-1"},{"key":"10.3238\/arztebl.m2024.0094_ref22","doi-asserted-by":"crossref","unstructured":"Manoharan J, Albers MB, Bollmann C, et al.: Single gland excision for MEN1-associated primary hyperparathyroidism. Clin Endocrinol (Oxf) 2020; 92: 63–70.","DOI":"10.1111\/cen.14112"},{"key":"10.3238\/arztebl.m2024.0094_ref23","doi-asserted-by":"crossref","unstructured":"Sadowski SM, Cadiot G, Dansin E, Goudet P, Triponez F: The future: surgical advances in MEN1 therapeutic approaches and management strategies. Endocr Relat Cancer 2017; 24: T243–60.","DOI":"10.1530\/ERC-17-0285"},{"key":"10.3238\/arztebl.m2024.0094_ref24","doi-asserted-by":"crossref","unstructured":"Fassnacht M, Tsagarakis S, Terzolo M, et al.: European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2023; 189: G1–42.","DOI":"10.1093\/ejendo\/lvad066"},{"key":"10.3238\/arztebl.m2024.0094_ref25","unstructured":"Erstellt von der Chirurgischen Arbeitsgemeinschaft Endokrinologie (CAEK) (federf\u00fchrend) der Deutschen Gesellschaft f\u00fcr Allgemein- und Viszeralchirurgie (DGAV): Operative Therapie von Nebennierentumoren. Version vom 17. Dezember 2017. 2017. www.register.awmf.org\/assets\/guidelines\/088-008l_S2k_Operative-Therapie_Nebennierentumoren_2019-07-abgelaufen.pdf (last accessed on 19 Jun 2023)."},{"key":"10.3238\/arztebl.m2024.0094_ref26","doi-asserted-by":"crossref","unstructured":"Triponez F, Goudet P, Dosseh D, et al.: Is surgery beneficial for MEN1 patients with small (< or = 2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg 2006; 30: 654–62; discussion 663–4.","DOI":"10.1007\/s00268-005-0354-9"},{"key":"10.3238\/arztebl.m2024.0094_ref27","doi-asserted-by":"crossref","unstructured":"Nell S, Verkooijen HM, Pieterman CRC, et al.: Management of MEN1 related nonfunctioning pancreatic NETs: a shifting paradigm: results from the DutchMEN1 study group. Ann Surg 2018; 267: 1155–60.","DOI":"10.1097\/SLA.0000000000002183"},{"key":"10.3238\/arztebl.m2024.0094_ref28","doi-asserted-by":"crossref","unstructured":"Partelli S, Tamburrino D, Lopez C, et al.: Active surveillance versus surgery of nonfunctioning pancreatic neuroendocrine neoplasms ≤ 2 cm in MEN1 patients. Neuroendocrinology 2016; 103: 779–86.","DOI":"10.1159\/000443613"},{"key":"10.3238\/arztebl.m2024.0094_ref29","doi-asserted-by":"crossref","unstructured":"Kos-Kudła B, Casta\u00f1o JP, Denecke T, et al.: European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. J Neuroendocrinol 2023; 35: e13343.","DOI":"10.1111\/jne.13343"},{"key":"10.3238\/arztebl.m2024.0094_ref30","doi-asserted-by":"crossref","unstructured":"Partelli S, Tamburrino D, Cherif R, et al.: Risk and predictors of postoperative morbidity and mortality after pancreaticoduodenectomy for pancreatic neuroendocrine neoplasms: a comparative study with pancreatic ductal adenocarcinoma. Pancreas 2019; 48: 504–9.","DOI":"10.1097\/MPA.0000000000001273"},{"key":"10.3238\/arztebl.m2024.0094_ref31","doi-asserted-by":"crossref","unstructured":"van Beek DJ, Nell S, Verkooijen HM, et al.: Surgery for multiple endocrine neoplasia type 1-related insulinoma: long-term outcomes in a large international cohort. Br J Surg 2020; 107: 1489–99.","DOI":"10.1002\/bjs.11632"},{"key":"10.3238\/arztebl.m2024.0094_ref32","doi-asserted-by":"crossref","unstructured":"Ramundo V, Del Prete M, Marotta V, et al.: Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours. Clin Endocrinol (Oxf) 2014; 80: 850–5.","DOI":"10.1111\/cen.12411"},{"key":"10.3238\/arztebl.m2024.0094_ref33","doi-asserted-by":"crossref","unstructured":"Anlauf M, Garbrecht N, Henopp T, et al.: Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features. World J Gastroenterol 2006; 12: 5440–6.","DOI":"10.3748\/wjg.v12.i34.5440"},{"key":"10.3238\/arztebl.m2024.0094_ref34","doi-asserted-by":"crossref","unstructured":"Kong W, Albers MB, Manoharan J, et al.: Pancreaticoduodenectomy is the best surgical procedure for Zollinger–Ellison syndrome associated with multiple endocrine neoplasia type 1. Cancers (Basel) 2022; 14: 1928.","DOI":"10.3390\/cancers14081928"},{"key":"10.3238\/arztebl.m2024.0094_ref35","doi-asserted-by":"crossref","unstructured":"Peipert BJ, Goswami S, Yount SE, Sturgeon C: Health-related quality of life in MEN1 patients compared with other chronic conditions and the United States general population. Surg (United States) 2018; 163: 205–11.","DOI":"10.1016\/j.surg.2017.04.030"},{"key":"10.3238\/arztebl.m2024.0094_ref36","doi-asserted-by":"crossref","unstructured":"Van Leeuwaarde RS, Pieterman CRC, Bleiker EMA, et al.: High fear of disease occurrence is associated with low quality of life in patients with multiple endocrine neoplasia type 1: results from the Dutch MEN1 study group. J Clin Endocrinol Metab 2018; 103: 2354–61.","DOI":"10.1210\/jc.2018-00259"},{"key":"10.3238\/arztebl.m2024.0094_ref37","unstructured":"Berglund G, Liden A, Hansson MG, Oberg K, Sjoden PO, Nordin K: Quality of life in patients with multiple endocrine neoplasia type 1 (MEN1). Fam Cancer 2003; 2: 27–33."},{"key":"10.3238\/arztebl.m2024.0094_ref38","doi-asserted-by":"crossref","unstructured":"Goswami S, Peipert BJ, Helenowski I, Yount SE, Sturgeon C: Disease and treatment factors associated with lower quality of life scores in adults with multiple endocrine neoplasia type I. Surgery 2017; 162: 1270–7.","DOI":"10.1016\/j.surg.2017.07.023"},{"key":"10.3238\/arztebl.m2024.0094_ref39","doi-asserted-by":"crossref","unstructured":"Manoharan J, Bollmann C, Kann PH, Di Fazio P, Bartsch DK, Albers MB: Gender differences in multiple endocrine neoplasia type 1: Implications for screening? Visc Med 2020; 36: 3–8.","DOI":"10.1159\/000505498"},{"key":"10.3238\/arztebl.m2024.0094_ref40","doi-asserted-by":"crossref","unstructured":"Ballard HS, Fame B, Hartsock RJ: Familial multiple endocrine adenoma-peptic ulcer complex. Medicine (Baltimore) 1964; 43: 481–516.","DOI":"10.1097\/00005792-196407000-00003"},{"key":"10.3238\/arztebl.m2024.0094_ref41","doi-asserted-by":"crossref","unstructured":"Stratakis CA, Schussheim DH, Freedman SM, et al.: Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 2000; 85: 4776–80.","DOI":"10.1210\/jc.85.12.4776"},{"key":"10.3238\/arztebl.m2024.0094_ref42","doi-asserted-by":"crossref","unstructured":"Newey PJ, Jeyabalan J, Walls GV, et al.: Asymptomatic children with multiple endocrine neoplasia type 1 mutations may harbor nonfunctioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab 2009; 94: 3640–6.","DOI":"10.1210\/jc.2009-0564"},{"key":"10.3238\/arztebl.m2024.0094_ref43","doi-asserted-by":"crossref","unstructured":"Goudet P, Dalac A, Le Bras M, et al.: MEN1 disease occurring before 21 years old: a 160-patient cohort study from the groupe d’\u00e9tude des tumeurs endocrines. J Clin Endocrinol Metab 2015; 100: 1568–77.","DOI":"10.1210\/jc.2014-3659"},{"key":"10.3238\/arztebl.m2024.0094_ref44","doi-asserted-by":"crossref","unstructured":"Gatta-Cherifi B, Chabre O, Murat A, et al.: Adrenal involvement in MEN1. Analysis of 715 cases from the groupe d’etude des tumeurs endocrines database. Eur J Endocrinol 2012; 166: 269–79.","DOI":"10.1530\/EJE-11-0679"},{"key":"10.3238\/arztebl.m2024.0094_ref45","doi-asserted-by":"crossref","unstructured":"Bordi C, Falchetti A, Azzoni C, et al.: Aggressive forms of gastric neuroendocrine tumors in multiple endocrine neoplasia type I. Am J Surg Pathol 1997; 21: 1075–82.","DOI":"10.1097\/00000478-199709000-00012"},{"key":"10.3238\/arztebl.m2024.0094_ref46","doi-asserted-by":"crossref","unstructured":"van Leeuwaarde RS, Dreijerink KM, Ausems MG, et al.: MEN1-dependent breast cancer: indication for early screening? Results from the dutch MEN1 study group. J Clin Endocrinol Metab 2017; 102: 2083–90.","DOI":"10.1210\/jc.2016-3690"},{"key":"10.3238\/arztebl.m2024.0094_ref47","doi-asserted-by":"crossref","unstructured":"Asgharian B, Chen YJ, Patronas NJ, et al.: Meningiomas may be a component tumor of multiple endocrine neoplasia type 1. Clin Cancer Res 2004; 10: 869–80.","DOI":"10.1158\/1078-0432.CCR-0938-3"},{"key":"10.3238\/arztebl.m2024.0094_ref48","doi-asserted-by":"crossref","unstructured":"Băicoianu-Nitescu LC, Gheorghe AM, Carsote M, Dumitrascu MC, Sandru F: Approach of multiple endocrine neoplasia type 1 (MEN1) syndrome-related skin tumors. Diagnostics (Basel) 2022; 12: 2768.","DOI":"10.3390\/diagnostics12112768"},{"key":"10.3238\/arztebl.m2024.0094_ref49","doi-asserted-by":"crossref","unstructured":"Newey PJ, Newell-Price J: MEN1 Surveillance Guidelines: Time to (re)think? J Endocr Soc 2022; 6: bvac001.","DOI":"10.1210\/jendso\/bvac001"},{"key":"10.3238\/arztebl.m2024.0094_ref50","doi-asserted-by":"crossref","unstructured":"Thevenon J, Bourredjem A, Faivre L, et al.: Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a groupe d’etude des tumeurs endocrines (GTE) cohort study. Hum Mol Genet 2013; 22: 1940–8.","DOI":"10.1093\/hmg\/ddt039"},{"key":"10.3238\/arztebl.m2024.0094_ref51","doi-asserted-by":"crossref","unstructured":"Bartsch DK, Slater EP, Albers M, et al.: Higher risk of aggressive pancreatic neuroendocrine tumors in MEN1 patients with MEN1 mutations affecting the CHES1 interacting MENIN domain. J Clin Endocrinol Metab 2014; 99: E2387–91.","DOI":"10.1210\/jc.2013-4432"},{"key":"10.3238\/arztebl.m2024.0094_ref52","doi-asserted-by":"crossref","unstructured":"Seabrook AJ, Harris JE, Velosa SB, et al.: Multiple Endocrine Tumors Associated with Germline MAX Mutations: Multiple Endocrine Neoplasia Type 5? J Clin Endocrinol Metab 2021; 106: e1163–82.","DOI":"10.1210\/clinem\/dgaa957"},{"key":"10.3238\/arztebl.m2024.0094_ref53","doi-asserted-by":"crossref","unstructured":"Sahakian N, Castinetti F, Romanet P, Reznik Y, Brue T: Updates on the genetics of multiple endocrine neoplasia. Ann Endocrinol (Paris) 2024; 85: 127–35.","DOI":"10.1016\/j.ando.2023.11.005"},{"key":"10.3238\/arztebl.m2024.0094_ref54","doi-asserted-by":"crossref","unstructured":"Waldmann J, Fendrich V, Habbe N, et al.: Screening of patients with multiple endocrine neoplasia type 1 (MEN-1): a critical analysis of its value. World J Surg 2009; 33: 1208–18.","DOI":"10.1007\/s00268-009-9983-8"},{"key":"10.3238\/arztebl.m2024.0094_ref55","doi-asserted-by":"crossref","unstructured":"Wu Y, Gao L, Guo X, et al.: Pituitary adenomas in patients with multiple endocrine neoplasia type 1: a single-center experience in China. Pituitary 2019; 22: 113–23.","DOI":"10.1007\/s11102-019-00939-x"},{"key":"10.3238\/arztebl.m2024.0094_ref56","doi-asserted-by":"crossref","unstructured":"Zielinski G, Ozdarski M, Maksymowicz M, Szamotulska K, Witek P: Prolactinomas: prognostic factors of early remission after transsphenoidal surgery. Front Endocrinol (Lausanne) 2020: 11: 439.","DOI":"10.3389\/fendo.2020.00439"},{"key":"10.3238\/arztebl.m2024.0094_ref57","doi-asserted-by":"crossref","unstructured":"Findlay MC, Sabahi M, Azab M, et al.: The role of surgical management for prolactin-secreting tumors in the era of dopaminergic agonists: an international multicenter report. Clin Neurol Neurosurg 2024: 236: 108079.","DOI":"10.1016\/j.clineuro.2023.108079"},{"key":"10.3238\/arztebl.m2024.0094_ref58","doi-asserted-by":"crossref","unstructured":"Fyrsten E, Norl\u00e9n O, Hessman O, St\u00e5lberg P, Hellman P: Long-term surveillance of treated hyperparathyroidism for multiple endocrine neoplasia type 1: recurrence or hypoparathyroidism? World J Surg 2016; 40: 615–21.","DOI":"10.1007\/s00268-015-3297-9"},{"key":"10.3238\/arztebl.m2024.0094_ref59","doi-asserted-by":"crossref","unstructured":"Santucci N, Ksiazek E, Pattou F, et al.: Recurrence after surgery for primary hyperparathyroidism in 517 patients with multiple endocrine neoplasia type 1: an association francophone de chirurgie endocrinienne and groupe d’\u00e9tude des tumeurs endocrines study. Ann Surg 2024; 279: 340–5.","DOI":"10.1097\/SLA.0000000000005980"},{"key":"10.3238\/arztebl.m2024.0094_ref60","doi-asserted-by":"crossref","unstructured":"Orloff LA, Wiseman SM, Bernet VJ, et al.: American thyroid association statement on postoperative hypoparathyroidism: diagnosis, prevention, and management in adults. Thyroid 2018; 28: 830–41.","DOI":"10.1089\/thy.2017.0309"},{"key":"10.3238\/arztebl.m2024.0094_ref61","doi-asserted-by":"crossref","unstructured":"Marini F, Giusti F, Tonelli F, Brandi ML: Management impact: effects on quality of life and prognosis in MEN1. Endocr Relat Cancer 2017; 24: T227–42.","DOI":"10.1530\/ERC-17-0203"},{"key":"10.3238\/arztebl.m2024.0094_ref62","doi-asserted-by":"crossref","unstructured":"Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L: Postsurgical hypoparathyroidism—risk of fractures, psychiatric diseases, cancer, cataract, and infections. J Bone Miner Res 2014; 29: 2504–10.","DOI":"10.1002\/jbmr.2273"},{"key":"10.3238\/arztebl.m2024.0094_ref63","doi-asserted-by":"crossref","unstructured":"Santucci N, Gaujoux S, Binquet C, et al.: Pancreatoduodenectomy for neuroendocrine tumors in patients with multiple endocrine neoplasia type 1: an AFCE (Association Francophone de Chirurgie Endocrinienne) and GTE (Groupe d’\u00e9tude des Tumeurs Endocrines) study. World J Surg 2021; 45: 1794–802.","DOI":"10.1007\/s00268-021-06005-7"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2024.0094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T07:35:18Z","timestamp":1722411318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2024.0094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":63,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2024.0094","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,9]]}}}